The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

Posterior scleritis is a rare but potentially sight-threatening condition that commonly causes diagnostic confusion due to its variable and perplexing clinical symptoms and signs. We present a case of ...